July 7, 2019  |  

Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai.

Authors: Scott, Stuart A and Owusu Obeng, Aniwaa and Botton, Mariana R and Yang, Yao and Scott, Erick R and Ellis, Stephen B and Wallsten, Richard and Kaszemacher, Tom and Zhou, Xiang and Chen, Rong and Nicoletti, Paola and Naik, Hetanshi and Kenny, Eimear E and Vega, Aida and Waite, Eva and Diaz, George A and Dudley, Joel and Halperin, Jonathan L and Edelmann, Lisa and Kasarskis, Andrew and Hulot, Jean-Sébastien and Peter, Inga and Bottinger, Erwin P and Hirschhorn, Kurt and Sklar, Pamela and Cho, Judy H and Desnick, Robert J and Schadt, Eric E

For almost 50 years, the Icahn School of Medicine at Mount Sinai has continually invested in genetics and genomics, facilitating a healthy ecosystem that provides widespread support for the ongoing programs in translational pharmacogenomics. These programs can be broadly cataloged into discovery, education, clinical implementation and testing, which are collaboratively accomplished by multiple departments, institutes, laboratories, companies and colleagues. Focus areas have included drug response association studies and allele discovery, multiethnic pharmacogenomics, personalized genotyping and survey-based education programs, pre-emptive clinical testing implementation and novel assay development. This overview summarizes the current state of translational pharmacogenomics at Mount Sinai, including a future outlook on the forthcoming expansions in overall support, research and clinical programs, genomic technology infrastructure and the participating faculty.

Journal: Pharmacogenomics
DOI: 10.2217/pgs-2017-0137
Year: 2017

Read publication

Talk with an expert

If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.